Cargando…

Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets

High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer and the most lethal gynecologic malignancy due to advanced stage at presentation. Recent years have witnessed progress in the therapy of HGSOC with the introduction of PARP (poly-adenosine diphosphate ribose polyme...

Descripción completa

Detalles Bibliográficos
Autor principal:	Voutsadakis, Ioannis A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585777/ https://www.ncbi.nlm.nih.gov/pubmed/33116896 http://dx.doi.org/10.2147/CMAR.S249540

Ejemplares similares

Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
por: Matthews, Bayley G., et al.
Publicado: (2021)

The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
por: Yan, Shunfei, et al.
Publicado: (2017)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

Cellular models of development of ovarian high‐grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis
por: Mei, Jie, et al.
Publicado: (2021)

Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer
por: Digklia, Antonia, et al.
Publicado: (2014)

High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
por: Lisio, Michael-Antony, et al.
Publicado: (2019)

Amplified therapeutic targets in high-grade serous ovarian carcinoma – a review of the literature with quantitative appraisal
por: Talbot, Thomas, et al.
Publicado: (2023)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer
por: Al-Dossary, Amal A., et al.
Publicado: (2021)

Principles of dormancy evident in high-grade serous ovarian cancer
por: Shepherd, Trevor G., et al.
Publicado: (2022)

Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis
por: Li, Jie, et al.
Publicado: (2012)

Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
por: Vanguri, Rami, et al.
Publicado: (2022)

Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis—Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding
por: Otsuka, Isao, et al.
Publicado: (2020)

Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer
por: Wada, Miku, et al.
Publicado: (2020)

The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma
por: Chesnokov, Mikhail S., et al.
Publicado: (2021)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
por: De Donato, Marta, et al.
Publicado: (2020)

Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer
por: Moran-Jones, Kim, et al.
Publicado: (2015)

High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
por: Hatano, Yuichiro, et al.
Publicado: (2018)

High-throughput approaches for precision medicine in high-grade serous ovarian cancer
por: Govindarajan, Meinusha, et al.
Publicado: (2020)

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
por: Fernandez, Marta Llaurado, et al.
Publicado: (2019)

Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer
por: Huang, Dongqing, et al.
Publicado: (2021)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations
por: Otsuka, Isao
Publicado: (2021)

MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma
por: Yokomizo, Ryo, et al.
Publicado: (2019)

Identification of Potential Prognostic Competing Triplets in High-Grade Serous Ovarian Cancer
por: Zhao, Jian, et al.
Publicado: (2021)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020)

Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas
por: Milanesio, Michela Camilla, et al.
Publicado: (2020)

Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research
por: Gadducci, Angiolo, et al.
Publicado: (2020)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
por: Gadducci, Angiolo, et al.
Publicado: (2019)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics
por: Gross, Amy L., et al.
Publicado: (2010)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
por: Neal, Adam, et al.
Publicado: (2021)

Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer
por: Coan, Michela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bi9351akdphrumh8sj4vqfbe19